Stocks Health care ANRO
NYSE · Health careAlto Neuroscience, Inc. (ANRO)
It posted a net loss of $84.2M. In fiscal 2025 capital spending exceeded operating cash flow by $51.8M. At June 30, 2026 it held $243.7M in cash against $16.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Alto Neuroscience, Inc.
- Net worth
- Alto Neuroscience, Inc. has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $219.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $51.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alto Neuroscience, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Alto Neuroscience, Inc. does
Alto Neuroscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$63.2M | -$2.19 | -$51.8M |
| 2024 | n/a | -$61.4M | -$2.50 | -$49.5M |
| 2024 | n/a | -$36.3M | -$9.73 | -$33.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Alto Neuroscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- August 27, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 20, 2026Passive stake (5% or more) SCHEDULE 13G
- July 14, 2026
Insider trades
What the people running Alto Neuroscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Exercised options | 55,000 | $127.6K |
| September 30, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Exercised options | 24,056 | $56.5K |
| September 30, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Soldpre-planned (10b5-1) | 23,170 | $597.3K |
| September 30, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Soldpre-planned (10b5-1) | 886 | $23.8K |
| September 29, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Exercised options | 56,455 | $132.7K |
| September 29, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Exercised options | 54,375 | $127.8K |
| September 29, 2026 | Smith Nicholas ConradPRESIDENT AND CFO | Soldpre-planned (10b5-1) | 110,830 | $2.9M |
| May 14, 2026 | Etkin AmitPRESIDENT AND CEO, Director | Gave as a gift | 400,000 | - |
Who owns ANRO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | May 15, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 6.2% | August 14, 2026 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 5.8% | July 20, 2026 |
| Amit Etkin13G, passive | 5.4% | November 14, 2024 |
| Vanguard Capital Management13G, passive | 5.02% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 114 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Alpha Wave Global, LP | 3,707,757 | 0 |
| Commodore Capital LP | 2,723,196 | 0 |
| BlackRock, Inc. | 2,121,009 | +1,454,821 |
| Perceptive Advisors LLC | 1,609,893 | -400,000 |
| Adage Capital Partners GP, L.L.C. | 1,600,000 | +1,215,000 |
| Vanguard Capital Management LLC | 1,389,477 | +182,452 |
| Spruce Street Capital LP | 1,353,047 | +27,837 |
| Vivo Capital, LLC | 1,208,858 | +173,307 |
| Franklin Resources Inc | 1,013,307 | -88,567 |
| Armistice Capital, LLC | 864,000 | -48,000 |
| Affinity Asset Advisors, LLC | 850,000 | +350,000 |
| Vestal Point Capital, LP | 785,000 | -1,279,075 |
| State Street Corp | 685,945 | +486,442 |
| Geode Capital Management, LLC | 678,199 | +385,300 |
| 72 Investment Holdings, LLC | 667,778 | 0 |
| Northern Trust Corp | 632,701 | +159,298 |
| Millennium Management LLC | 558,320 | -263,662 |
| Point72 Asset Management, L.P. | 502,950 | -137 |
| Venrock Adviser, LLC | 500,000 | 0 |
| Integral Health Asset Management, LLC | 500,000 | 0 |
Insiders
2 insiders reported holding 913,009 shares in total, about $26.1M at the last price.
| Holder | Shares |
|---|---|
| Etkin AmitPRESIDENT AND CEO, Director | 833,949 |
| Smith Nicholas ConradPRESIDENT AND CFO | 79,060 |
Questions about ANRO
What does Alto Neuroscience, Inc. do?
Alto Neuroscience, Inc. is a company in the Health care sector, listed on NYSE as ANRO. Its shares trade on NYSE under the ticker ANRO.
What is Alto Neuroscience, Inc.'s net worth?
Alto Neuroscience, Inc. has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $219.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alto Neuroscience, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $84.2M.
When did Alto Neuroscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 30, 2026.
When is Alto Neuroscience, Inc.'s next earnings report?
Alto Neuroscience, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANRO with
Follow ANRO
Get an email when Alto Neuroscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alto Neuroscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.